Ovarian cancer vaccine - Northwest Biotherapeutics

Drug Profile

Ovarian cancer vaccine - Northwest Biotherapeutics

Alternative Names: Autologous dendritic cell vaccine (DCVax-L) for recurrent ovarian or primary peritoneal cancer - Northwest Biotherapeutics; Autologous dendritic cell vaccine leaded with autologous tumour cell lysate (DCVax-L) - Northwest Biotherapeutics; DCVac-L - Northwest Biotherapeutics; DCVax-L (Ovarian); DCVax-L (Peritoneal); DCVax-Ovarian

Latest Information Update: 28 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northwest Biotherapeutics
  • Developer Northwest Biotherapeutics; University of Pennsylvania Cancer Center
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Ovarian cancer
  • Phase I Peritoneal cancer

Most Recent Events

  • 28 Feb 2017 Phase-I/II development is ongoing in USA (Intradermal)
  • 10 Nov 2014 Phase-I/II clinical trials in Ovarian cancer (Metastatic disease, Recurrent) in USA (Intradermal) prior to November 2014
  • 11 Feb 2013 Phase-I development is completed for metastatic Ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top